1-15 of 15
Sandra M. Swain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Eleftherios P. Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas, Charles E. Geyer, Jr, Louis Fehrenbacher, Stephen K. Chia, Adam M. Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker Dakhil, Soonmyung Paik, Sandra M. Swain, Dennis C. Sgroi, Catherine A. Schnabel, Norman Wolmark
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1984–1991.
https://doi.org/10.1158/1078-0432.CCR-23-1977
Published: 01 May 2024
View article titled, Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Open the PDF for Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial in another window
Includes: Supplementary data
Journal Articles

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

Sandra M. Swain, Gong Tang, Heather Ann Brauer, David S. Goerlitz, Peter C. Lucas, André Robidoux, Brent T. Harris, Hanna Bandos, Yuqi Ren, Charles E. Geyer, Jr, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4233–4241.
https://doi.org/10.1158/1078-0432.CCR-20-0152
Published: 14 August 2020
View article titled, NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Open the PDF for NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response in another window
Includes: Supplementary data
Journal Articles

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

Melody Cobleigh, Denise A. Yardley, Adam M. Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (5): 1105–1113.
https://doi.org/10.1158/1078-0432.CCR-19-2350
Published: 02 March 2020
View article titled, Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
Open the PDF for Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs in another window
Includes: Supplementary data
Journal Articles

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (8): 2433–2441.
https://doi.org/10.1158/1078-0432.CCR-18-2366
Published: 15 April 2019
View article titled, Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs
Open the PDF for Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs in another window
Includes: Supplementary data
Journal Articles

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Matthew J. Brauer, Guanglei Zhuang, Maike Schmidt, Jenny Yao, Xiumin Wu, Joshua S. Kaminker, Stefanie S. Jurinka, Ganesh Kolumam, Alicia S. Chung, Adrian Jubb, Zora Modrusan, Tomoko Ozawa, C. David James, Heidi Phillips, Benjamin Haley, Rachel N.W. Tam, Anne C. Clermont, Jason H. Cheng, Sherry X. Yang, Sandra M. Swain, Daniel Chen, Stefan J. Scherer, Hartmut Koeppen, Ru-Fang Yeh, Peng Yue, Jean-Philippe Stephan, Priti Hegde, Napoleone Ferrara, Mallika Singh, Carlos Bais
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (13): 3681–3692.
https://doi.org/10.1158/1078-0432.CCR-12-3635
Published: 30 June 2013
View article titled, Identification and Analysis of <em>In Vivo</em> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Open the PDF for Identification and Analysis of <em>In Vivo</em> VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies in another window
Includes: Supplementary data
Journal Articles

Reply to the Letter to the Editor from Jubb

Sherry X. Yang, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 414.
https://doi.org/10.1158/1078-0432.CCR-08-2602
Published: 31 December 2008
View article titled, Reply to the Letter to the Editor from Jubb
Open the PDF for Reply to the Letter to the Editor from Jubb in another window
Journal Articles

Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer

Sherry X. Yang, Seth M. Steinberg, Dat Nguyen, Thomas D. Wu, Zora Modrusan, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5893–5899.
https://doi.org/10.1158/1078-0432.CCR-07-4762
Published: 14 September 2008
View article titled, Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
Open the PDF for Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Chia C. Portera, Janice M. Walshe, Douglas R. Rosing, Neelima Denduluri, Arlene W. Berman, Ujala Vatas, Margarita Velarde, Catherine K. Chow, Seth M. Steinberg, Diana Nguyen, Sherry X. Yang, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2710–2716.
https://doi.org/10.1158/1078-0432.CCR-07-4636
Published: 01 May 2008
View article titled, Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Open the PDF for Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer in another window
Journal Articles

The Epothilones: Translating from the Laboratory to the Clinic

James J. Lee, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1618–1624.
https://doi.org/10.1158/1078-0432.CCR-07-2201
Published: 17 March 2008
View article titled, The Epothilones: Translating from the Laboratory to the Clinic
Open the PDF for The Epothilones: Translating from the Laboratory to the Clinic in another window
Journal Articles

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems

Brian R.J. Healey Bird, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 14–24.
https://doi.org/10.1158/1078-0432.CCR-07-1033
Published: 02 January 2008
View article titled, Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Open the PDF for Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems in another window
Journal Articles

Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel

Michael C. Cox, Jennifer Low, James Lee, Janice Walshe, Neelima Denduluri, Arlene Berman, Matthew G. Permenter, William P. Petros, Douglas K. Price, William D. Figg, Alex Sparreboom, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4636–4640.
https://doi.org/10.1158/1078-0432.CCR-06-0388
Published: 09 August 2006
View article titled, Influence of Garlic (<em>Allium sativum</em>) on the Pharmacokinetics of Docetaxel
Open the PDF for Influence of Garlic (<em>Allium sativum</em>) on the Pharmacokinetics of Docetaxel in another window
Journal Articles

Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer

Sherry X. Yang, Richard M. Simon, Antoinette R. Tan, Diana Nguyen, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6226–6232.
https://doi.org/10.1158/1078-0432.CCR-05-0270
Published: 06 September 2005
View article titled, Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer
Open the PDF for Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Peter F. Lebowitz, Jennifer Eng-Wong, Sandra M. Swain, Arlene Berman, Maria J. Merino, Catherine K. Chow, David Venzon, Farah Zia, David Danforth, Edison Liu, JoAnne Zujewski
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (20): 6764–6769.
https://doi.org/10.1158/1078-0432.CCR-04-0976
Published: 22 October 2004
View article titled, A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer
Open the PDF for A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer in another window
Journal Articles

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer

Antoinette R. Tan, Xiaowei Yang, Arlene Berman, Suoping Zhai, Alex Sparreboom, Allyson L. Parr, Catherine Chow, Jaime S. Brahim, Seth M. Steinberg, William D. Figg, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5038–5047.
https://doi.org/10.1158/1078-0432.CCR-04-0025
Published: 05 August 2004
View article titled, Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer
Open the PDF for Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer in another window
Journal Articles

Microvessel Density, Expression of Estrogen Receptor α, MIB-1, p53, and c-erbB-2 in Inflammatory Breast Cancer

Nicole J. McCarthy, Xiaowei Yang, Ilona R. Linnoila, Maria J. Merino, Stephen M. Hewitt, Allyson L. Parr, Soonmyung Paik, Seth M. Steinberg, Dan P. Hartmann, Nejib Mourali, Paul H. Levine, Sandra M. Swain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3857–3862.
Published: 01 December 2002
View article titled, Microvessel Density, Expression of Estrogen Receptor α, MIB-1, p53, and c-erbB-2 in Inflammatory Breast Cancer
Open the PDF for Microvessel Density, Expression of Estrogen Receptor α, MIB-1, p53, and c-erbB-2 in Inflammatory Breast Cancer in another window